NCT06769620View on ClinicalTrials.gov

A First in Human Study of ORT247 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

October 24, 2023

Study Completion Date

October 24, 2023

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

ORT247

ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.

DRUG

Placebo

Placebo consists of normal saline

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors
lead

Orthogonal Neuroscience Inc.

INDUSTRY